Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $218.43, for a total transaction of $655,290.00. Following the completion of the sale, the insider owned 137,643 shares in the company, valued at $30,065,360.49. This represents a 2.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The shares were sold at an average price of $202.84, for a total transaction of $335,091.68.
• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The stock was sold at an average price of $203.69, for a total transaction of $693,564.45.
• On Monday, April 27th, Solomon Moshkevich sold 2,182 shares of Natera stock. The stock was sold at an average price of $204.10, for a total transaction of $445,346.20.
• On Wednesday, April 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $202.30, for a total value of $606,900.00.
• On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The stock was sold at an average price of $204.13, for a total value of $186,778.95.

Natera Stock Performance

Shares of NTRA opened at $211.85 on Thursday. The stock has a 50-day moving average of $203.28 and a two-hundred day moving average of $215.94. Natera, Inc. has a one year low of $131.81 and a one year high of $256.36. The stock has a market cap of $30.34 billion, a P/E ratio of -129.97 and a beta of 1.56.

Analyst Ratings Changes

NTRA has been the subject of several research reports. JPMorgan Chase & Co. lifted their price objective on shares of Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Piper Sandler restated an “overweight” rating and set a $249.00 price objective on shares of Natera in a research note on Tuesday, May 12th. Morgan Stanley decreased their price objective on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. William Blair initiated coverage on shares of Natera in a research note on Tuesday, April 14th. They set an “outperform” rating for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.81.

Hedge Funds Weigh In On Natera

Several institutional investors have recently made changes to their positions in the company. Reflection Asset Management purchased a new stake in Natera in the 4th quarter worth $29,000. Palladiem LLC purchased a new stake in Natera in the 4th quarter worth $31,000. Horizon Investments LLC purchased a new stake in Natera in the 3rd quarter worth $32,000. International Assets Investment Management LLC increased its holdings in Natera by 132.9% in the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares in the last quarter. Finally, Bank of Jackson Hole Trust increased its holdings in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after acquiring an additional 83 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.